Latest event summaries
Event summaries combining transcripts, slides, and related documents. Updated as new events are published.
- Record billings, top retention, and AI-driven growth led to Q4 non-GAAP profitability.DOMO
Q4 2026 - Record underwriting and investment gains fueled double-digit book value growth in 2025.GLRE
Q4 2025 - Combined ratio improved to 92.2%, but wildfire losses reduced net income and book value.GBLI
Q4 2025 - Cemsidomide and CFT8919 advance as best-in-class degraders for MM and NSCLC, with strong pipeline momentum.CCCC
Corporate presentation - Record passenger and revenue growth in 2025, with strong outlook and major state ownership change.KBHL
Q4 2025 - Record 2025 profits, 7% dividend hike, and strong 2026 growth and investment outlook.3045
Q4 2025 - Profitability expected in Q2 as bottlenecks are resolved and $10M strategic financing secured.ROOF
Status update - Record Q4 results and robust order backlog set the stage for continued growth in 2026.HAV
Q4 2025 - Higher selling prices and innovation drove margin and net income gains amid strong liquidity.FIZZ
Q3 2026 - Expanded CNSide coverage and REYOBIQ clinical progress drove 2025, with a $22.4M net loss.PSTV
Q4 2025 - Adjusted operating profit grew 3.0% despite a 3.8% revenue decline, with strong cash generation.SRAD
H2 2025 - Clinical progress in glioblastoma and improved financials set up key milestones for 2026.INAB
Q4 2025 - Advanced clinical pipeline and maintained strong liquidity, with key data readouts ahead.ORKA
Q4 2025 - Reduced net loss, strong cash position, and key clinical milestones expected in 2026.ELTX
Q4 2025 - Azenosertib shows >30% ORR and ~6 months mDOR in Cyclin E1+ PROC, advancing to Phase 3.ZNTL
Corporate presentation - FDA approval and launch of TONMYA marked a pivotal year, boosting revenue and pipeline progress.TNXP
Q4 2025